Psyence Biomed adds Australian site for psilocybin trial

Press Release NEW YORK – Psyence Biomedical Ltd. (NASDAQ:PBM), a biotechnology company specializing in nature-derived psychedelic medicines, has announced the addition of Empax Center in Perth, Australia, as a second site for its Phase IIb clinical trial. The trial is investigating the use of psilocybin, a naturally occurring psychedelic compound, for the treatment of Adjustment […]